Therapy Areas: Central Nervous System
Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
30 November 2021 - - US-based clinical-stage biopharmaceutical company Karuna Therapeutics, Inc. (NASDAQ: KRTX) has appointed Charmaine Lykins as chief commercial officer, effective November 29, 2021, the company said.

Lykins brings over 25 years of psychiatry and neuroscience-focused pharmaceutical launch experience across multiple organizations recognized as leaders in developing and commercializing medicines for central nervous system disorders, including Eli Lilly (NYSE: LLY), Lundbeck, Sunovion and Adadia Pharmaceuticals.

Lykins most recently served as the senior vice president, Global Product Planning and chief marketing officer for Adadia, where she oversaw their healthcare professional and consumer marketing, marketing operations and new product planning functions.

Prior to Adadia, she led commercialization and planning efforts for Lundbeck's portfolio of schizophrenia treatments from early development through commercialization.

Her US and global commercialization and strategic planning experience consists of 10 product launches, including Rexulti in schizophrenia, depression, and agitation in Alzheimer's disease, Ablify Maintena in schizophrenia and bipolar disorder, Latuda, Cymbalta, and Zyprexa, among other medicines representing first-in-class therapies for psychiatric and neurological conditions.

Lykins received her MBA with an emphasis in international business from University of South Carolina and received her B.A. in chemistry and honors humanities from Ball State University.

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
Login
Username:

Password: